NYSEAMERICAN:XTNT Xtant Medical (XTNT) Stock Price, News & Analysis → The Presidential candidate you should REALLY be worried about (From Stansberry Research) (Ad) Free XTNT Stock Alerts $0.75 -0.02 (-2.59%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$0.73▼$0.7850-Day Range N/A52-Week Range$0.60▼$1.45Volume88,588 shsAverage Volume99,437 shsMarket Capitalization$97.81 millionP/E RatioN/ADividend YieldN/APrice Target$2.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get Xtant Medical alerts: Email Address Xtant Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside179.6% Upside$2.10 Price TargetShort InterestHealthy0.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.04 out of 5 stars 3.5 Analyst's Opinion Consensus RatingXtant Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageXtant Medical has only been the subject of 1 research reports in the past 90 days.Read more about Xtant Medical's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.63% of the float of Xtant Medical has been sold short.Short Interest Ratio / Days to CoverXtant Medical has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xtant Medical has recently increased by 5.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXtant Medical does not currently pay a dividend.Dividend GrowthXtant Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XTNT. Previous Next 2.9 News and Social Media Coverage News SentimentXtant Medical has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Xtant Medical this week, compared to 1 article on an average week.Search Interest1 people have searched for XTNT on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Xtant Medical to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xtant Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.80% of the stock of Xtant Medical is held by insiders.Percentage Held by Institutions69.33% of the stock of Xtant Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xtant Medical's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Xtant Medical is -75.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xtant Medical is -75.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXtant Medical has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Xtant Medical Stock (NYSEAMERICAN:XTNT)Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.Read More XTNT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XTNT Stock News HeadlinesMay 24 at 3:43 AM | americanbankingnews.comXtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above 200 Day Moving Average of $0.00May 22 at 8:06 PM | finanznachrichten.deXtant Medical Holdings, Inc.: Xtant Medical to Participate in 21st Annual Craig-Hallum Institutional Investor Conference on May 29May 22 at 8:06 PM | finance.yahoo.comXtant Medical to Participate in 21st Annual Craig-Hallum Institutional Investor Conference on May 29May 19, 2024 | americanbankingnews.comXtant Medical (NYSEAMERICAN:XTNT) Price Target Raised to $3.00 at BTIG ResearchMay 16, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Xtant Medical Holdings (XTNT), Teleflex (TFX) and Esperion (ESPR)May 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT) and Verrica Pharmaceuticals (VRCA)May 16, 2024 | msn.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comXtant Medical Holdings Inc (XTNT) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...May 15, 2024 | markets.businessinsider.comWhat Wall Street expects from Xtant Medical's earningsMay 15, 2024 | finanznachrichten.deXtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue GuidanceMay 15, 2024 | finance.yahoo.comXtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue GuidanceMay 15, 2024 | americanbankingnews.comXtant Medical (NYSEAMERICAN:XTNT) Stock Crosses Above Two Hundred Day Moving Average of $0.00May 1, 2024 | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on Xtant Medical Holdings (XTNT)May 1, 2024 | wsj.comXtant Medical Holdings Inc.April 30, 2024 | finanznachrichten.deXtant Medical, Inc.: Xtant Medical Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute WoundsApril 30, 2024 | globenewswire.comXtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute WoundsApril 2, 2024 | finance.yahoo.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comQ4 2023 Xtant Medical Holdings Inc Earnings CallApril 1, 2024 | investorplace.comXTNT Stock Earnings: Xtant Medical Hldgs Misses EPS, Beats Revenue for Q4 2023April 1, 2024 | finance.yahoo.comXtant Medical Holdings Inc (XTNT) Reports Record Revenue in 2023, Outpacing Analyst EstimatesApril 1, 2024 | globenewswire.comXtant Medical Announces Record Full Year 2023 Revenue of $91.3 MillionMarch 30, 2024 | finance.yahoo.comXtant Medical Holdings, Inc. (XTNT)March 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Trulieve Cannabis (TCNNF), Xtant Medical Holdings (XTNT)March 21, 2024 | globenewswire.comXtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024March 7, 2024 | globenewswire.comXtant Medical Increases Revolving Credit Facility to $17 Million with MidCap FinancialSee More Headlines Receive XTNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xtant Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today5/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSEAMERICAN:XTNT Previous SymbolAMEX:XTNT CUSIPN/A CIK1453593 Webxtantmedical.com Phone(406) 388-0480Fax406-388-1354Employees207Year FoundedN/APrice Target and Rating Average Stock Price Target$2.10 High Stock Price Target$3.00 Low Stock Price Target$1.20 Potential Upside/Downside+179.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$660,000.00 Net Margins-1.64% Pretax Margin-3.26% Return on Equity-3.60% Return on Assets-1.93% Debt Debt-to-Equity Ratio0.35 Current Ratio2.34 Quick Ratio0.98 Sales & Book Value Annual Sales$91.30 million Price / Sales1.07 Cash Flow$0.03 per share Price / Cash Flow26.47 Book Value$0.37 per share Price / Book2.03Miscellaneous Outstanding Shares130,220,000Free Float117,456,000Market Cap$97.81 million OptionableNot Optionable Beta0.30 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Sean E. Browne (Age 58)President, CEO & Director Comp: $1.29MMr. Mark A. Schallenberger (Age 38)Chief Operations Officer Comp: $778.42kMr. Kevin D. Brandt (Age 58)Senior VP & Chief Commercial Officer Comp: $658.03kMr. Scott C. Neils (Age 40)Chief Financial Officer Comp: $517.86kMs. Catherine LundyVice President of Human ResourcesKey CompetitorsAthira PharmaNASDAQ:ATHAOutlook TherapeuticsNASDAQ:OTLKJATT AcquisitionNYSE:JATTArmata PharmaceuticalsNYSEAMERICAN:ARMPAlloVirNASDAQ:ALVRView All CompetitorsInstitutional OwnershipAWM Investment Company Inc.Sold 90,474 shares on 5/16/2024Ownership: 0.290%Juniper Investment Company LLCBought 348,399 shares on 5/16/2024Ownership: 0.268%Vanguard Group Inc.Bought 48,319 shares on 5/10/2024Ownership: 1.189%AMH Equity LtdSold 94,029 shares on 5/7/2024Ownership: 0.384%View All Institutional Transactions XTNT Stock Analysis - Frequently Asked Questions Should I buy or sell Xtant Medical stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xtant Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XTNT shares. View XTNT analyst ratings or view top-rated stocks. What is Xtant Medical's stock price target for 2024? 1 brokers have issued twelve-month target prices for Xtant Medical's stock. Their XTNT share price targets range from $1.20 to $3.00. On average, they anticipate the company's share price to reach $2.10 in the next year. This suggests a possible upside of 179.6% from the stock's current price. View analysts price targets for XTNT or view top-rated stocks among Wall Street analysts. How were Xtant Medical's earnings last quarter? Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) issued its earnings results on Wednesday, May, 15th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter. The medical device company earned $27.87 million during the quarter. Xtant Medical had a negative trailing twelve-month return on equity of 3.60% and a negative net margin of 1.64%. When did Xtant Medical's stock split? Xtant Medical shares reverse split on the morning of Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What guidance has Xtant Medical issued on next quarter's earnings? Xtant Medical issued an update on its FY 2024 earnings guidance on Tuesday, May, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $116.0 million-$120.0 million, compared to the consensus revenue estimate of $115.0 million. What other stocks do shareholders of Xtant Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xtant Medical investors own include Aurinia Pharmaceuticals (AUPH), LadRx (CYTR), Heat Biologics (HTBX), Neovasc (NVCN), Rexahn Pharmaceuticals (REXN), Biopharmx (BPMX), Adamis Pharmaceuticals (ADMP), Lipocine (LPCN) and Synergy Pharmaceuticals (SGYP). Who are Xtant Medical's major shareholders? Xtant Medical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.19%), AMH Equity Ltd (0.38%), AWM Investment Company Inc. (0.29%) and Juniper Investment Company LLC (0.27%). Insiders that own company stock include Scott C Neils, Sean E Browne and Stavros G Vizirgianakis. View institutional ownership trends. How do I buy shares of Xtant Medical? Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:XTNT) was last updated on 5/25/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThis could mean the end of the U.S dollar…Colonial MetalsVIPs Only (Do NOT Share This)Profits Run[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaWrite this ticker symbol down…StocksToTrade$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyA personal note from Behind The Markets' CEO Dylan Jovine...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xtant Medical Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.